A new study showed that among psoriasis therapies, biologics and a stepwise regimen combining phototherapy with biologics provided the greatest efficacy and quality-of-life gains, although ...

The company’s strategic focus sharpened on ZYNLONTA, with a reiteration of peak revenue targets and an expanded discussion of market opportunities in second-line and indolent lymphoma indications. R&D ...

Innovative glycobiology platform aimed at enhancing the efficacy, safety, and scalability of next-generation antibody therapeutics across multiple disease areas ...

Theriva received a $300,000 upfront payment at signing and is eligible for up to $38M in development, regulatory, and sales milestones along with tiered single-digit royalties on net product sales - - ...

Halia Therapeutics, a clinical-stage biopharmaceutical company advancing therapies grounded in human biology, today announced ...

A research lab in Seoul is inserting tiny genetic devices into cells. These devices record molecular reactions occurring ...

G&A Expenses -- $13.8 million in the fourth quarter, of which $5.6 million was non-cash stock-based compensation; annual G&A ...

Apogee Therapeutics develops biologic therapeutics targeting atopic dermatitis, chronic obstructive pulmonary disease, and related immunology indications, with lead candidates APG777 and APG808 in ...

Capricor Therapeutics’ deramiocel was rejected in July 2025, potentially caught between Nicole Verdun, a former top biologics regulator at the FDA, and Vinay Prasad, director of the Center for ...

The intellectual property will enhance Liberate Bio’s LNP platform for selective programming of monocytes and macrophages.

Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026Budoprutug clinical trials ongoing in pMN, ...

Apogee Therapeutics (NASDAQ:APGE) outlined a series of near- and mid-term clinical milestones at TD Cowen’s 46th Annual ...